By elevating the expression of ANO7, a potential prostate cancer susceptibility gene, it may be possible to predict disease severity and outcome.
A dose-dense neoadjuvant chemotherapy regimen yielded higher response rates compared with a standard regimen in a cohort of bladder cancer patients.
This article summarizes the key side effects associated with ADT for the treatment of prostate cancer and discusses strategies to optimize management.
A particular gatekeeper—the nuclear pore protein called POM121—traffics molecules that increase tumor aggressiveness in prostate cancer.
ZHX2 has been identified as a possible new therapeutic target for clear cell RCC patients.
Cross-sectional, long-term imaging is shown to be important for patients with high-risk resected non–clear cell RCC.
Concentrations of KIM-1 in the blood may predict for renal cell carcinoma up to 5 years prior to diagnosis.
A meta-analysis identified several factors that are correlated with locoregional recurrence in patients with nonmetastatic muscle-invasive bladder cancer.
An existing body of literature shows that marital status and related social support are connected with disease outcomes.
Intravenous Iobenguane I 131 has been approved to treat unresectable, locally advanced, or metastatic pheochromocytoma.